Application
Western blot analysis of NIP30 Antibody (C-term) in WiDr cell line lysates (35ug/lane). NIP30 (arrow) was detected using the purified Pab.Application
NIP30 Antibody (C-term) IHC analysis in formalin fixed and paraffin embedded Colon carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the NIP30 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.| Product Name | NIP30 Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | C16orf94, NIP30 |
|---|---|
| Alternative Names | FAM192A C16orf94 NIP30 Protein FAM192A NEFA-interacting nuclear protein NIP30 |
| Molecular Weight(MW) | 28912 Da |
| Tissue Specificity | This NIP30 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 161~191 amino acids from the C-terminal region of human NIP30. |
| Cellular Localization | Nucleus (Potential). |
| Entrez Gene | 80011 |
|---|
Application
Western blot analysis of NIP30 Antibody (C-term) in WiDr cell line lysates (35ug/lane). NIP30 (arrow) was detected using the purified Pab.
Application
NIP30 Antibody (C-term) IHC analysis in formalin fixed and paraffin embedded Colon carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the NIP30 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
